Pioneering Medical Innovations
Instylla, Inc. is a privately held company focused on delivering next-generation liquid embolics for interventional radiology, with initial clinical applications in interventional oncology and peripheral hemostasis.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology.
Acquired by Boston Scientific in 2018, Augmenix, Inc. developed and commercialized the SpaceOAR® System, a therapy used to reduce common and debilitating side effects that men may experience after receiving prostate cancer radiotherapy.
New technology offered in three unique shapes expands the company’s comprehensive stroke system, allowing physicians to achieve fast and consistent
Award Honors Top Executives Fueling Innovation and Impact in the Life Sciences Industry Axtria, a global leader in cloud software
151 subjects enrolled in various stages of loading and randomization in SOL-1 pivotal study of AXPAXLI in wet AMD as
Join us on June 12-13 in Princeton, New Jersey, for an inspiring event featuring life sciences experts, thought leaders, and
Clinical investigators achieve significant milestone by enrolling 150 patients with hypervascular tumors in pivotal randomized study. BEDFORD, Mass., – May
Recent Leadership Appointments Put Ocular on Track to Become a Leader in Retinal Care Site Activation and Patient Enrollment for